P. Blume-Jensen

发表

T. Hunter, P. Blume-Jensen, 2001, Nature.

Pathway-Based Identification of Biomarkers for Targeted Therapeutics: Personalized Oncology with PI3K Pathway Inhibitors

Theresa Zhang, John Rush, Igor Feldman, 2010, Science Translational Medicine.

Kit/stem cell factor receptor‐induced phosphatidylinositol 3′‐kinase signalling is not required for normal development and function of interstitial cells of Cajal in mouse gastrointestinal tract

Steven Mark Miller, G. Farrugia, P. Blume-Jensen, 2003, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

The platelet-derived growth factor beta-receptor kinase insert confers specific signaling properties to a chimeric fibroblast growth factor receptor.

L. Claesson‐Welsh, P. Blume-Jensen, S. Wennström, 1992, The Journal of biological chemistry.

Discovery of PDK1 Kinase Inhibitors with a Novel Mechanism of Action by Ultrahigh Throughput Screening

I. Kariv, P. Blume-Jensen, J. Andersen, 2010, The Journal of Biological Chemistry.

Kinase-Regulated Signal Transduction Pathways

P. Blume-Jensen, 2002 .

Phosphoproteomics of primary AML patient samples reveals rationale for AKT combination therapy and p53 context to overcome selinexor resistance

Dorte B. Bekker-Jensen, Kristina B. Emdal, J. Olsen, 2022, Cell reports.

Design of BET Inhibitor Bottlebrush Prodrugs with Superior Efficacy and Devoid of Systemic Toxicities.

Jeremiah A. Johnson, Matthew R. Golder, M. Shipitsin, 2021, Journal of the American Chemical Society.

Design of BET Inhibitor Prodrugs with Superior Efficacy and Devoid of Systemic Toxicities

Matthew R. Golder, M. Shipitsin, B. Vangamudi, 2020 .

Modulation of Kit/stem cell factor receptor-induced signaling by protein kinase C.

C. Heldin, I. Gout, M. Waterfield, 1994, The Journal of biological chemistry.

Proopiomelanocortin producing cells of spleen: increase after transplantation with opioid-peptide producing Ehrlich ascites tumor cells.

P. Blume-Jensen, L. Larsson, T. Skovsgaard, 1988, European journal of cell biology.

Epidermal Growth Factor-Induced Tumor Cell Invasion and Metastasis Initiated by Dephosphorylation and Downregulation of Focal Adhesion Kinase

Tony Hunter, Zhimin Lu, T. Hunter, 2001, Molecular and Cellular Biology.

Kit/stem cell factor receptor-induced activation of phosphatidylinositol 3′-kinase is essential for male fertility

T. Hunter, P. Blume-Jensen, S. O’Gorman, 2000, Nature Genetics.

Phosphorylation of Shc by Src family kinases is necessary for stem cell factor receptor/c-kit mediated activation of the Ras/MAP kinase pathway and c-fos induction

P. Blume-Jensen, L. Rönnstrand, J. Lennartsson, 1999, Oncogene.

Activation of the human c‐kit product by ligand‐induced dimerization mediates circular actin reorganization and chemotaxis.

C. Heldin, A. Siegbahn, K. Zsebo, 1991, The EMBO journal.

PDK1 attenuation fails to prevent tumor formation in PTEN-deficient transgenic mouse models.

K. Kunii, R. Bronson, M. Scott, 2011, Cancer research.

Therapeutics , Targets , and Chemical Biology PDK 1 Attenuation Fails to Prevent Tumor Formation in PTEN-Deficient Transgenic Mouse Models

Hare, K. Kunii, R. Bronson, 2011 .

Genetic and Pharmacological Inhibition of PDK1 in Cancer Cells

C. Paweletz, Youwei Yan, M. Wiznerowicz, 2010, The Journal of Biological Chemistry.

Identification of Direct Target Engagement Biomarkers for Kinase-Targeted Therapeutics

R. Hendrickson, C. Paweletz, P. Blume-Jensen, 2011, PloS one.

Identification of proteomic biomarkers predicting prostate cancer aggressiveness and lethality despite biopsy-sampling error

M. Loda, M. Shipitsin, D. Rimm, 2014, British Journal of Cancer.

Development and Clinical Validation of an In Situ Biopsy-Based Multimarker Assay for Risk Stratification in Prostate Cancer

M. Loda, P. Kantoff, F. Saad, 2015, Clinical Cancer Research.

Automated quantitative multiplex immunofluorescence in situ imaging identifies phospho-S6 and phospho-PRAS40 as predictive protein biomarkers for prostate cancer lethality

M. Shipitsin, D. Rimm, P. Blume-Jensen, 2014, Proteome Science.

Reduction of liver fibrosis by rationally designed macromolecular telmisartan prodrugs

Jeremiah A. Johnson, Matthew R. Golder, M. Shipitsin, 2018, Nature Biomedical Engineering.

The Kit receptor promotes cell survival via activation of PI 3-kinase and subsequent Akt-mediated phosphorylation of Bad on Ser136

T. Hunter, P. Blume-Jensen, R. Janknecht, 1998, Current Biology.

Automated quantitative multiplex immunofluorescence in situ imaging identifies phospho-S6 and phospho-PRAS40 as predictive protein biomarkers for prostate cancer lethality

David L Rimm, Eldar Giladi, M. Shipitsin, 2014, Proteome Science.

Signal Transduction Mechanisms Initiated by Receptor Tyrosine Kinases

P. Blume-Jensen, 2002 .

Fibroblast growth factor receptor-1 regulation of Src family kinases.

P. Blume-Jensen, S. Courtneidge, E. Landgren, 1995, Oncogene.

Identification of the Major Phosphorylation Sites for Protein Kinase C in Kit/Stem Cell Factor Receptor in Vitro and in Intact Cells (*)

C. Wernstedt, C. Heldin, P. Blume-Jensen, 1995, The Journal of Biological Chemistry.

Two-dimensional phosphoamino acid analysis.

P. Blume-Jensen, T. Hunter, 2001, Methods in molecular biology.

Involvement of phosphatidylinositol 3'-kinase in stem-cell-factor-induced phospholipase D activation and arachidonic acid release.

C. Heldin, P. Blume-Jensen, L. Rönnstrand, 1997, European journal of biochemistry.

Increased Kit/SCF receptor induced mitogenicity but abolished cell motility after inhibition of protein kinase C.

C. Heldin, A. Siegbahn, P. Blume-Jensen, 1993, The EMBO journal.

Increased proliferation of interstitial cells of Cajal due to altered desensitization of c-Kit

G. Farrugia, P. Blume-Jensen, S. Gibbons, 2006 .

Reduction of liver fibrosis by rationally designed macromolecular telmisartan prodrugs

Jeremiah A. Johnson, Matthew R. Golder, M. Shipitsin, 2018, Nature Biomedical Engineering.

Pathway-Based Identification of Biomarkers for Targeted Therapeutics: Personalized Oncology with PI3K Pathway Inhibitors

C. Paweletz, I. Feldman, J. Rush, 2010, Science Translational Medicine.